Date: 2015-07-15
Type of information: Licensing agreement
Compound: organoid technology
Company: Galapagos (Belgium) HUB foundation for use of Organoid Technology (The Netherlands )
Therapeutic area: Inflammatory diseases - Gastrointestinal diseases - Rare diseases - Genetic diseases
Type agreement: licensing
Action mechanism:
Disease: cystic fibrosis, inflammatory bowel disease
Details: * On July 15, 2015, Galapagos announced that it has entered into a licensing agreement with the HUB foundation for use of Organoid Technology for pre-clinical research in cystic fibrosis (CF) and inflammatory bowel disease (IBD). Organoids are mini-organs grown in cell culture from biopsies taken from patients; these mini-organs faithfully recapitulate the genetic and phenotypic characteristics of diseased tissues. Organoids have proven to be valuable disease models for the high-throughput screening and validation of innovative medicines, bypassing limitations associated with cell-line and xenograft-based pre-clinical drug studies.
Financial terms:
Latest news:
